Erbitux FDA Approval
Links shared publicly online about this topic
FDA approves Erbitux to treat late-stage head and neck cancer
fda.gov — “The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.” View full resource at fda.gov
Most Recently Shared on November 7, 2011 at 7:27 pm By:
NCI Cancer Bulletin Health News
FDA approves Erbitux, in combination w/ chemotherapy, to treat late-stage head & neck cancer (release) http://t.co/bMtFRAyA
US FDA approval for expanded use of Erbitux | Oral Cancer News
oralcancernews.org — “US FDA approval for expanded use of Erbitux | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on November 9, 2011 at 8:24 am By:
Erbitux (Cetuximab) Approved For Metastatic Head And Neck Cancer, USA
medicalnewstoday.com — “Erbitux (cetuximab) has been approved by the US FDA for combination use with chemotherapy for late-stage head and neck cancer treatment. When given together with chemotherapy, Erbitus was found to” View full resource at medicalnewstoday.com
Most Recently Shared on November 8, 2011 at 7:05 am By:
MNT Drug Approvals Health News
Erbitux (cetuximab) Approved For Metastatic Head And Neck Cancer, USA http://t.co/zZZhKwbc #regulatory
Erbitux Approved for Metastatic Head and Neck Cancer - MPR
empr.com — “Bristol-Myers Squibb announced that Erbitux (cetuximab) has gained an expanded indication for the treatment of metastatic head and neck cancer in combination with other chemotherapy.” View full resource at empr.com
Most Recently Shared on November 7, 2011 at 8:28 pm By:
Erbitux Gains Expanded Indication for Metastatic Head and Neck Cancer http://t.co/nqnyHzHm #oncology
FDA Approves Cetuximab for Metastatic Head and Neck Cancer | Oral Cancer News
oralcancernews.org — “FDA Approves Cetuximab for Metastatic Head and Neck Cancer | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on November 8, 2011 at 2:00 pm By:
ImClone and Bristol-Myers's Erbitux and Amgen's Vectibix Label Change Approved for KRAS Gene - Health Blog - WSJ
blogs.wsj.com — “Patients with mutations to the KRAS gene won't benefit from these medicines.” View full resource at blogs.wsj.com
Most Recently Shared on July 20, 2009 at 2:47 pm By:
Erbitux, Vectibix Label Change Approved for KRAS Gene http://bit.ly/bXIJ4
New Use for Erbitux Stalled by FDA’s Data Request - Health Blog - WSJ
feeds.wsjonline.com — “The cancer drug was a key reason Eli Lilly acquired ImClone.” View full resource at feeds.wsjonline.com
Most Recently Shared on March 2, 2009 at 7:02 pm By:
New Use for Erbitux Stalled by FDA’s Data Request http://bit.ly/4GTnQ
Hypersensitivity Reactions to Erbitux Caused by Tick Bites. | Oral Cancer News
oralcancernews.org — “Hypersensitivity Reactions to Erbitux Caused by Tick Bites. | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on July 1, 2011 at 3:42 pm By:
Erbitux Indication Extension Submitted For 1st-Line Advanced Or Metastatic NSCLC In The EU
medicalnewstoday.com — “Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency (EMA) for the approval of Erbitux® (c” View full resource at medicalnewstoday.com
Most Recently Shared on March 30, 2011 at 10:05 am By:
Erbitux Indication Extension Submitted For 1st-Line Advanced Or Metastatic NSCLC In The EU http://mnt.to/3STY #lungcancer
FDA Approves Cetuximab for Late-Stage Head and Neck Cancer | Oral Cancer News
oralcancernews.org — “FDA Approves Cetuximab for Late-Stage Head and Neck Cancer | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on November 9, 2011 at 1:05 pm By:
Europe Gives Thumbs-Down to Erbitux for Treating Lung Cancer - Health Blog - WSJ
blogs.wsj.com — “The unexpected refusal for approval send shares of Germany's Merck plummeting.” View full resource at blogs.wsj.com
Most Recently Shared on July 24, 2009 at 3:45 pm By:
Europe Gives Surprise Thumbs-Down to Erbitux for Treating Lung Cancer http://bit.ly/W3t4S
FDA lets KRAS gene narrow drug use - FiercePharma
fiercepharma.com — “Personalized cancer treatment took a giant step forward today. FDA has OK'd a label change for Erbitux and Vectibix, narrowing the indication for advanced colon cancer. The label now recommends the... Read more...” View full resource at fiercepharma.com
Most Recently Shared on July 20, 2009 at 5:40 pm By:
HealthEd Health Business and Medical Education
RT @FiercePharma #FDA has OK'd a label change for #Erbitux, narrowing the indication for advanced colon cancer. http://is.gd/1Fo2B #pharma
FDA Approves Emergency Contraceptive:
health.msn.com — “FDA Approves Emergency Contraceptive:” View full resource at health.msn.com
Most Recently Shared on August 14, 2010 at 1:44 pm By:
FDA Approves Emergency Contraceptive: http://bit.ly/bOqq6o
Hernia Mesh Approved by FDA
hcplive.com — “he Biomerix Ventral Hernia Repair Mesh has received FDA approval to be marketed” View full resource at hcplive.com
Most Recently Shared on July 21, 2010 at 4:03 pm By:
Hernia Mesh Approved by FDA http://hcp.lv/9hMpow
FDA approves ablation catheters
theheart.org — “UPDATED // The Food and Drug Administration today approved the first ablation catheters for the treatment of atrial fibrillation.” View full resource at theheart.org
Most Recently Shared on February 6, 2009 at 11:35 pm By:
FDA approves AF ablation catheters http://tinyurl.com/c65a4f
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
NCI Cancer Bulletin
Cancer research news and information from the news staff of the NCI Cancer Bulletin. Tweets by Carmen Phillips and Edward Winstead
-
The Oral Cancer Foundation
Information- Support- Advocacy- Research- Hope The foundation is an IRS registered non-profit 501(c) 3, public service charity designed for advocacy and service, created to promote change, through proactive means, in both the public and medical/dental professional sectors. At the forefront of our agenda is the firm establishment in the minds of the American public for the need to undergo an annual oral cancer screening, combined with an outreach to the dental and medical communities to provide this service as a matter of routine practice. Oral cancer takes more lives than cancers we routinely hear about, such as cervical, Hodgkin's lymphoma, skin (malignant melanoma), testicular, and many others. In the efforts to reduce the death rate from cancers in the US, the most significant progress has been made through early detection. Cervical, skin, prostate, and others that lend themselves to simple, opportunistic screenings and exams have all had their death rates reduced through programs promoting early discovery. Early discovery and diagnosis, yields better long-term outcomes, and lower morbidity to those who undergo treatments. Oral cancer is not hidden within the body in some hard to find location requiring an invasive examination, the majority of the time it is literally in plain view, right under your nose, and can be seen with the naked eye or felt with the fingers. In most cases, its early, highly survivable stages are easily detected in a 3 to 5 minute painless visual and tactile examination. Even the precancerous lesions, which can progress into malignancy, can be seen with the naked eye. An annual oral examination conducted by members of the dental and medical communities will have a definite impact on reducing the death rate associated with oral cancer. It is our mission to bring this about.
-
MNT Drug Approvals
The latest regulatory affairs / drug approvals news published daily. Articles from research centers, universities and prestigious journals.
Advertisement
